Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme

被引:43
|
作者
Rahnasto, M
Raunio, H
Poso, A
Wittekindt, C
Juvonen, RO
机构
[1] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
[2] Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland
关键词
D O I
10.1021/jm049536b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was to develop screening and in silico modeling methods to obtain accurate information on the active center of CYP2A6, a nicotine oxidizing enzyme. The inhibitory potencies of 26 naphthalene and 16 non-naphthalene derivatives were determined for human CYP2A6 and mouse CYP2A5 enzymes. Several comparative molecular field analysis (CoMFA) models were developed to find out what types of steric and electrostatic properties are required for potent inhibitors. The IC50 values of the tested compounds varied from 0.55 to 35 400 muM for CYP2A6 and from 1 to 1500 muM for CYP2A5. The generated CoMFA models were able to accurately predict the inhibition potencies of an external test set of chemicals. Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy.
引用
收藏
页码:440 / 449
页数:10
相关论文
共 50 条
  • [11] Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors
    Stempler, Shiri
    Levy-Sakin, Michal
    Frydman-Marom, Anat
    Amir, Yaniv
    Scherzer-Attali, Roni
    Buzhansky, Ludmila
    Gazit, Ehud
    Senderowitz, Hanoch
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2011, 25 (02) : 135 - 144
  • [12] Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors
    Ekins, Sean
    Mankowski, Dayna C.
    Hoover, Dennis J.
    Lawton, Michael P.
    Treadway, Judith L.
    Harwood, H. James, Jr.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (03) : 493 - 500
  • [13] The role of CYP2A6*2 in nicotine metabolism
    Riexinger, A
    Collins, S
    Gaertner, I
    Farger, G
    Batra, A
    NICOTINE & TOBACCO RESEARCH, 2005, 7 (04) : 653 - 653
  • [14] Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: A comprehensive analysis
    Prasanna, S
    Manivannan, E
    Chaturvedi, SC
    DRUG DEVELOPMENT RESEARCH, 2005, 64 (04) : 220 - 231
  • [15] Quantitative structure-activity relationship analysis of canonical inhibitors of serine proteases
    Dell'Orco, Daniele
    De Benedetti, Pier Giuseppe
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2008, 22 (6-7) : 469 - 478
  • [16] Nicotine metabolite ratio as a predictor of CYP2A6 phenotypic activity.
    Dempsey, DA
    Tutka, P
    Jacob, P
    Benowitz, NL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P24 - P24
  • [17] Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
    Mwenifiumbo, Jill C.
    Tyndale, Rachel F.
    PHARMACOGENOMICS, 2007, 8 (10) : 1385 - 1402
  • [18] CYP2A6 polymorphism and nicotine metabolism.
    Benowitz, NL
    Tyndale, R
    Jacob, P
    Swan, GE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P41 - P41
  • [19] QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP OF INHIBITORS OF NONENZYMATIC GLYCATION
    RAVI, VN
    WALLER, CL
    BEATY, C
    GOLDBERG, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1994, 35 (04) : 1929 - 1929
  • [20] CYP2A6 polymorphism, nicotine, and environmental nitrosamines
    Idle, JR
    LANCET, 1999, 353 (9169): : 2073 - 2073